Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-1-19
pubmed:abstractText
To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene under control of the survivin promoter was constructed. Ad-SUR-NIS mediating iodide uptake and cytotoxicity was performed in vitro. Scintigraphic, biodistribution and radioiodine therapy studies were performed in vivo. PC-3 (prostate); HepG2 (hepatoma) and A375 (melanoma) cancer cells all exhibited perchlorate-sensitive iodide uptake after infection with Ad-SUR-NIS, approximately 50 times higher than that of negative control Ad-CMV-GFP-infected cells. No significant iodide uptake was observed in normal human dental pulp fibroblast (DPF) cells after infection with Ad-SUR-NIS. Clonogenic assays demonstrated that Ad-SUR-NIS-infected cancer cells were selectively killed by exposure to (131)I. Ad-SUR-NIS-infected tumors show significant radioiodine accumulation (13.3 ± 2.85% ID per g at 2 h post-injection), and the effective half-life was 3.1 h. Moreover, infection with Ad-SUR-NIS in combination with (131)I suppressed tumor growth. These results indicate that expression of NIS under control of the survivin promoter can likely be used to achieve cancer-specific expression of NIS in many types of cancers. In combination with radioiodine therapy, this strategy is a possible method of cancer gene therapy.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-10397257, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-10567210, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-10807060, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-10893432, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-10910060, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11103823, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11172305, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11228531, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11567995, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11571539, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11733216, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11751382, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-11929953, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-12390328, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-14583762, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-14604966, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-14633711, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-15017380, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-15359286, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-15510175, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-15746050, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-15941870, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-16039041, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-16156268, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-16489092, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-16644756, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-17160413, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-17698909, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-17989705, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-18029468, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-18404268, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-18698017, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-18810799, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-19241193, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-8559252, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-8607025, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-8806637, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-9256286, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-9525374, http://linkedlifedata.com/resource/pubmed/commentcorrection/21037556-9973215
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1476-5500
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
144-52
pubmed:dateRevised
2011-7-25
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.
pubmed:affiliation
Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't